Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some po ...

Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors. Haemophilia is a rare bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. H ...

Core Insights - Novo Resources Corp. has released its 2024 Sustainability Report, highlighting its commitment to sustainability and the importance of stakeholder engagement, including local communities and traditional owners [1][2]. Company Overview - Novo Resources Corp. is an Australian-based gold explorer listed on the ASX and TSX, focusing on discovering standalone gold projects with over 1 million ounces (Moz) development potential [4]. - The company holds a significant land package of approximately 6,700 square kilometers in the Pilbara region of Western Australia, along with the 22 square kilometer Belltopper project in Victoria, Australia [4]. Recent Developments - Over the past year, Novo transitioned from an operator to a gold explorer, divesting the Nullagine Gold Project and completing multiple joint ventures (JVs) [2]. - The company is advancing its key project area, the Egina Gold Camp, where it has formed a JV with De Grey Mining at the Becher Project, involving an exploration expenditure of A$25 million over four years for a 50% interest [5]. - Novo is also progressing gold exploration at Nunyerry North, part of the Croydon JV, where significant gold mineralization was identified in 2023 [5]. Strategic Focus - Novo has formed lithium joint ventures with Liatam and SQM in the Pilbara, providing exposure to battery metals for shareholders [5]. - The company maintains a disciplined program to identify value-accretive opportunities aimed at building further value for shareholders [5].

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The the stock of drugmaker has fallen by 12.51% in the past month, lagging the Medical sector's loss of 3.35% and the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The co ...

Novo Nordisk (NVO) ended the recent trading session at $117.20, demonstrating a -0.48% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.97% for the day. At the same time, the Dow added 0.3%, and the tech-heavy Nasdaq gained 1.45%.The the stock of drugmaker has fallen by 10.72% in the past month, lagging the Medical sector's loss of 3.72% and the S&P 500's gain of 5.41%.Market participants will be closely following the financial results of Novo N ...

The initiative will launch in six cities across five continentsInterventions aim to increase physical activity and healthy eating among childrenThe three-year initiative comes with an investment of more than 250 million Danish kroner Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together wit ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Share Repurchase Program - Novo Nordisk initiated a share repurchase program on August 7, 2024, with a total budget of up to DKK 20 billion over a 12-month period starting February 6, 2024[2][7] - As of September 27, 2024, Novo Nordisk has repurchased a total of 12,671,184 B shares at an average price of DKK 880.84, amounting to a transaction value of DKK 11,161,264,179[7] - The company has accumulated 1,604,058 B shares under the repurchase program, with a total transaction value of DKK 1,433,558,129 since the last announcement[4][7] - Novo Nordisk currently holds 13,999,815 B shares as treasury shares, representing 0.3% of the total share capital[6] - The average purchase price for the shares repurchased since the program's initiation is DKK 805.09[4] - The share repurchase program is part of Novo Nordisk's strategy to enhance shareholder value and return capital to shareholders[2] Company Overview - Novo Nordisk employs approximately 69,000 people and markets its products in around 170 countries, indicating a strong global presence[8] - The company is listed on Nasdaq Copenhagen and its ADRs are traded on the New York Stock Exchange, enhancing its visibility in international markets[8] Commitment to Healthcare - Novo Nordisk's commitment to driving change in healthcare is reflected in its ongoing investments in scientific breakthroughs and expanding access to medicines[8] - The company continues to focus on chronic disease management, particularly in diabetes, aligning its business strategy with its heritage[8]

The thrust of the company's long-term strategy is becoming clearer.By now, pretty much everyone has heard of Novo Nordisk's (NVO -2.09%) widely popular drug for type 2 diabetes, Ozempic. And, as many investors appreciate, when a pharma company mints a winning product, it's only logical for it to leverage the expertise required to develop the product into making new medicines that are even better.On that note, Novo is already moving very aggressively to invent sequels to Ozempic by flexing its financial migh ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.Novo Nordisk (NVO 1.20%) just made a partnership play worth $600 million with a small biotech called NanoVation that might just change the stock's trajectory for many years to come. On Sept. 18, the pair signed a deal that could eventually pave the way for Novo to make a next-gen medicine that it hopes will one-up Ozempic, its best-selling drug for type 2 diabetes.Competitors like Eli Lilly (LLY 0.01%) ar ...